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Pediatric Diabetes
Editorial
Introduction to ISPAD Clinical Practice
Consensus Guidelines 2014 Compendium
This supplement of Pediatric Diabetes is an update of
the guideline chapters that were originally individually
published in the journal between 2006 and 2008, and as
a single compendiumedition in 2009.The chapters have
been modified and updated to reflect the significant
advances in scientific knowledge and clinical care that
have occurred since then. These updated guidelines
also are available on the International Society for
Pediatric and Adolescent Diabetes (ISPAD) website:
www.ispad.org.
In 2007, the total child population of the world
(0–14 yr) was estimated to be 1.8 billion, of whom
0.02% had diabetes. This means that approximately
497 000 children around the world have diabetes,
with 79 000 new cases diagnosed each year (1).
However, field data suggest that some individual
country estimates (especially in developing countries)
are uncertain or inaccurate. These very large numbers
of children need help to survive with insulin injections
in order to live a full life without restrictions or
disabling complications and without being stigmatized
for their diabetes.
Even today, almost a century after the discovery
of insulin, the most common cause of death in a
child with diabetes from a global perspective is a lack
of access to insulin (2). Many children die before
their diabetes is diagnosed. It is therefore of utmost
importance that all forces unite to make it come true
that no child should die from diabetes. A promising
initiative has been taken by the International Diabetes
Federation (IDF) ‘Life for a Child’ programme
(www.lifeforachild.org) in collaboration with ISPAD
and other organizations. Several major companies that
produce insulin and other diabetes-related products
have pledged their support, and the number of children
and youth provided with insulin, test strips, and other
support is around 13 000 in 2014 and will continue
to increase. Currently 46 countries are involved.
ISPAD has also pledged support and assistance in the
training of pediatricians and health care professionals
in childhood and adolescent diabetes through its
membership network. CDiC (Changing Diabetes in
Children) is another initiative providing insulin and
diabetes care to India, Bangladesh, and a number of
countries in Africa. Additional initiatives by ISPAD
to improve diabetes care for children and adolescents
worldwide include its ‘science schools’ for physicians
and for other health care professions, its postgraduate
courses and its Diabetes in Practice (DIP) programme,
which have been held in a number of countries
around the world. ISPAD also provides tutoring in
collaboration with the European Society for Pediatric
Endocrinology (ESPE) at Pediatric Endocrine and
Diabetes Training Center in Africa (PETCA) in
Nairobi and at Pediatric Endocrine and Diabetes
Training Center in West Africa (PETCWA) in Lagos
for fellows from Africa in pediatric diabetology and
endocrinology.
In 1993, members of the ISPAD formulated the
Declaration of Kos, proclaiming their commitment to
‘promote optimal health, social welfare, and quality
of life for all children with diabetes around the world
by the year 2000’. Although all the aims and ideals of
the Declaration of Kos were not reached by 2000, we
feel that slowly, by small steps, the worldwide care of
children with diabetes is improving.
ISPAD published its first set of guidelines in 1995
(3), its second in 2000 (4), and its third in 2009 (5).
Since then, the acceptance of intensive therapy, also
for very young children, has increased around the
world. Insulin pump usage has risen in all age groups
in countries where this treatment modality can be
afforded. Intensive therapy requires better and more
comprehensive education for it to be successful.
The ISPAD Consensus Guidelines 2000 was
translated into 11 languages, reflecting the need for a
truly international document. In 2003–2005, national
guidelines for childhood diabetes were released: the
Australian Clinical Practice Guidelines from the
National Health and Medical Research Council (5),
and in the UK, the National Institute for Clinical
Excellence (NICE) Clinical Guideline (6). Both these
publications were truly evidence-based in that they deal
with the body of evidence with a systematic approach,
grading each reference and building the case for each
recommendation. In 2003, the Canadian Diabetes
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Association published Clinical Practice Guidelines
with chapters both on type 1 and type 2 diabetes
in children and adolescents (7). In 2005, the American
Diabetes Association (ADA) published its statement
on the care of children and adolescents with type 1
diabetes (8) which has recently been updated and now
shares the ISPAD hemoglobin A1c (HbA1c) target of
<7.5% for all children and adolescents (9). ISPAD in
collaboration with IDF has also produced the Global
IDF/ISPAD Guideline for Diabetes in Childhood
and Adolescence, introducing three levels of care:
recommended care, comprehensive care, and limited
care. In this edition of the ISPADGuidelines, a ‘limited
care’ section can also be found in the Supporting
information.
This fourth edition of ISPAD’s ‘Clinical Practice
Consensus Guidelines’ is much larger, and has been
enriched by the national guidelines mentioned above.
All chapters are organized as follows: executive
summary and recommendations, supporting body
of the chapter, references, and as an appendix for
limited care. As in past ISPAD guidelines, we have
used the ADA system for grading evidence (noted
below) (11). Whenever possible the reference for
a statement or recommendation has been included,
but as the reader will see, a vast majority of the
recommendations and suggestions are graded as ‘E’,
as they are solely based on expert consensus or clinical
experience.
The ISPAD guidelines serve a critical function to
gather in one document comprehensive advice on
diabetes care that is not only focused on children
and young people, but is also based on the latest
evidence and on a wide consensus of clinical practice.
They are also intended for worldwide application and
have thus been drafted by international writing teams,
modified by experts in different specialties from many
countries and were posted for review by members via
the ISPADwebsite. As far as possible, significant input
by individuals has been acknowledged. The Editors
wish to give their many thanks to the large number
of individuals who have contributed but whose names
could not be included.
The 2014 guidelines, as with previous editions, place
patient, family, and health care provider education
at the center of clinical management. Education is
the vehicle for optimal self-management, the key to
success.
We hope therefore that the guidelines will be widely
consulted and will be used to:
• improve awareness among governments, state health
care providers, and the general public of the serious
long-term implications of poorly managed diabetes
and of the essential resources needed for optimal
care;
• assist individual care givers in managing children
and adolescents with diabetes in a prompt,
safe, consistent, equitable, standardized manner in
accordance with the current views of experts in the
field; and
• provide evidence-based advice to improve the care
of children with diabetes.
As in 2009, ‘these guidelines are not strict protocols
nor are they the final word’. Individual clinical
judgment and decisionmaking also require the family’s
values and expectations to be considered with the best
outcomes being reached by consensus.
The American Diabetes Association evidence grading
system for clinical practice recommendations is as follows:
Level of
evidence Description
A Clear evidence from well-conducted,
generalizable, randomized, controlled trials
that are adequately powered, including:
• Multicenter trial
• Meta-analysis incorporating quality ratings
• Compelling non-experimental evidence (i.e.,
‘allor-none’ rule) developed by the Center
for Evidence-Based Medicine at Oxford*
Supportive evidence from well-conducted,
randomized, controlled trials that are
adequately powered, including:
• Well-conducted trials at ≥1 institutions
B Supportive evidence from well-conducted
cohort studies including:
• Prospective cohort studies or registry
• Meta-analysis of cohort studies
Supportive evidence from a well-conducted
case–control study.
C Supportive evidence from poorly controlled or
uncontrolled studies including:
• Randomized clinical trials with one major or
three minor methodological flaws that could
invalidate the results
• Observational studies with high potential
for bias
• Case series or case reports
Conflicting evidence with the weight of
evidence supporting the recommendation.
E Expert consensus or clinical experience.
*Either all patients died before therapy and at least some
survived with therapy or some patients died without therapy
and none died with therapy (e.g., the use of insulin in the
treatment of diabetes ketoacidosis).
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